Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock (VKTX)
· seekingalpha.com
Viking Therapeutics faces dilution risk, rising costs, and tough obesity drug competition. Read here for a detailed analysis of VKTX stock.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...